Clinical Trial Update: A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema [Phase 3]

View source ↗

Summary

Phase 3 trial of icatibant (TAK-667) in Japanese children and adolescents with acute attacks of hereditary angioedema has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2022-03-29